to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 signal transduction to inflammatory mediators that summon B and T cells. Tocilizumab has a nonlinear pharmacokinetic ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

IL-6 binds to either a membrane-bound IL-6 receptor (IL-6R), initiating anti-inflammatory classical signaling, or to a soluble IL-6 receptor (sIL-6R), triggering pro-inflammatory trans-signaling.